Company intelligence / Profile preview

Friedman Bioventure Fund

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Friedman Bioventure Fund is an active venture capital and private equity fund focusing on investing in early-stage life science, biotechnology, MedTech, genomics, oncology, and platform technology companies. Its portfolio companies are developing therapeutics and devices with promising biomedical technologies, including bispecific antibodies for cancer, genomics platforms, neurodegenerative disease innovations, and more[1][2][3][4][6].

Industry: Investors

Partnerships

Abbvie (C2N Diagnostics)Allergan (Retrosense Therapeutics)Novartis (DTx Pharma)bioMérieux (Banyan Biomarkers)Zentalis (Kalyra)Velos (Oncternal)Cellink AB (Echo Labs)

Beyond the preview

Go deeper on Friedman Bioventure Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Friedman Bioventure Fund.

Explore the full profile